First Republic Investment Management Inc. increased its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 9.6% in the 2nd quarter, HoldingsChannel reports. The firm owned 9,563 shares of the biopharmaceutical company’s stock after buying an additional 836 shares during the quarter. First Republic Investment Management Inc.’s holdings in Regeneron Pharmaceuticals were worth $3,299,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors also recently made changes to their positions in REGN. Ostrum Asset Management purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at $108,000. Icon Wealth Partners LLC purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at $112,000. Summit Trail Advisors LLC grew its position in shares of Regeneron Pharmaceuticals by 22,971.8% in the first quarter. Summit Trail Advisors LLC now owns 166,348 shares of the biopharmaceutical company’s stock valued at $166,000 after purchasing an additional 165,627 shares in the last quarter. Financial Gravity Wealth Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the first quarter valued at $211,000. Finally, Greenleaf Trust purchased a new position in shares of Regeneron Pharmaceuticals in the second quarter valued at $231,000. Institutional investors own 66.90% of the company’s stock.

Regeneron Pharmaceuticals stock opened at $392.17 on Friday. Regeneron Pharmaceuticals Inc has a 52 week low of $281.89 and a 52 week high of $477.00. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.62 and a quick ratio of 2.92. The stock has a market cap of $42.02 billion, a P/E ratio of 29.24, a price-to-earnings-growth ratio of 1.30 and a beta of 1.23.

Regeneron Pharmaceuticals (NASDAQ:REGN) last posted its earnings results on Thursday, August 2nd. The biopharmaceutical company reported $5.45 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $4.60 by $0.85. Regeneron Pharmaceuticals had a return on equity of 29.30% and a net margin of 25.65%. The business had revenue of $1.61 billion during the quarter, compared to analysts’ expectations of $1.56 billion. During the same period in the previous year, the business earned $4.17 earnings per share. The firm’s revenue was up 9.4% on a year-over-year basis. equities research analysts predict that Regeneron Pharmaceuticals Inc will post 19.4 earnings per share for the current fiscal year.

In other Regeneron Pharmaceuticals news, Chairman P Roy Vagelos sold 74,710 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, June 21st. The stock was sold at an average price of $327.87, for a total transaction of $24,495,167.70. Following the completion of the sale, the chairman now owns 553,121 shares of the company’s stock, valued at $181,351,782.27. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Joseph L. Goldstein sold 2,000 shares of Regeneron Pharmaceuticals stock in a transaction dated Thursday, July 5th. The stock was sold at an average price of $360.00, for a total value of $720,000.00. Following the sale, the director now directly owns 14,000 shares of the company’s stock, valued at approximately $5,040,000. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 259,432 shares of company stock valued at $96,485,427. Corporate insiders own 12.42% of the company’s stock.

Several equities analysts have recently weighed in on REGN shares. Barclays set a $290.00 price target on Regeneron Pharmaceuticals and gave the company a “sell” rating in a research report on Wednesday, May 23rd. BidaskClub upgraded Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 21st. SunTrust Banks reiterated a “hold” rating and issued a $400.00 price target on shares of Regeneron Pharmaceuticals in a research report on Friday, August 3rd. ValuEngine upgraded Regeneron Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, September 6th. Finally, Canaccord Genuity lifted their price target on Regeneron Pharmaceuticals from $304.00 to $390.00 and gave the company a “hold” rating in a research report on Friday, August 3rd. Two investment analysts have rated the stock with a sell rating, sixteen have given a hold rating and seven have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and a consensus price target of $411.48.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc, a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for treating serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion.

Read More: Do You Need a Fiduciary?

Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.